Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785577 · ClinicalTrials.gov registry record · Phase 2
A Study for Treatment of Pain in Patients With Diabetic Neuropathy.
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 273
- Enrollment target
NCT00785577: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00785577 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 273 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (105% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00785577, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 273 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether a new treatment will be safe and effective in treating pain. Patients with diabetic peripheral neuropathy will be included.
Primary Outcome
This scale measured 24-hour APS scores. Data were recorded daily (preferably at bedtime) on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). Least Squares (LS) Means were adjusted for baseline, investigator, treatment, visit, a treatment-by-visit interaction, and a baseline-by-visit interaction.
Interventions
- DRUG Placebo
- DRUG Pregabalin
- DRUG LY545694 49 mg
- DRUG LY545694 105 mg
- DRUG LY545694 21 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
What the finished NCT00785577 record still lists
NCT00785577 is an interventional study that assigns participants to a tested intervention. The registered 273 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (105% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00785577 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00785577 about?
NCT00785577 is a clinical study titled "A Study for Treatment of Pain in Patients With Diabetic Neuropathy.". The purpose of this study is to test whether a new treatment will be safe and effective in treating pain. Patients with diabetic peripheral neuropathy will be included.
What is the current status of trial NCT00785577?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 273 participants. The study started on 2008-11. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00785577?
The interventions under investigation include: Placebo (DRUG), Pregabalin (DRUG), LY545694 49 mg (DRUG), LY545694 105 mg (DRUG), LY545694 21 mg (DRUG).
Who is sponsoring clinical trial NCT00785577?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00785577's enrollment target sits among peer trials
273 204th of 2000 higher than 1,797 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07229430 · 273 participants · NA
Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia